Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC0662-0419 · 6 trials · 3 indications
Measured as number of events.
Measured as percentage-point (%-point).
Measured as %-point.
Measured as %-point.
Measured as number of events.
Measured as percentage (%).
Measured as count of participants.
Measured as picograms per milliliter (h\*pg/mL)
Measured as h\*pg/mL
Measured in hours\*nanomoles per liter (h\*nmol/L).
Number of events
Number of events
| Arm | Type | Description |
|---|---|---|
| NNC0662-0419 | EXPERIMENTAL | Participants will receive NNC0662-0419 administered subcutaneously in a dose-escalation manner. |
| NNC0662-0419 placebo | PLACEBO_COMPARATOR | Participants will receive NNC0662-0419 placebo administered subcutaneously in a dose-escalation manner. |
| Semaglutide | EXPERIMENTAL | Participants will receive semaglutide administered subcutaneously in a dose-escalation manner. |
| Semaglutide placebo | PLACEBO_COMPARATOR | Participants will receive semaglutide placebo administered subcutaneously in a dose-escalation manner. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive placebo matched to their respective investigational medicinal product s.c. once weekly. |
| NNC0662-0419 with oral contraceptive (Altavera) and acetaminophen | EXPERIMENTAL | Participants will receive once-weekly subcutaneous NNC0662-0419, with multiple doses administered over the treatment period. An oral contraceptive will be administered as a number of tablets per treatment period, with dosing conducted under supervised conditions. In addition, a single dose of acetaminophen will be administered as part of a standardized meal during treatment period. |
| NNC0662-0419 (Dose 1) | EXPERIMENTAL | Participants will receive a single dose (SD) of NNC0662-0419 subcutaneously. |
| NNC0662-0419 (Dose 2) | EXPERIMENTAL | Participants will receive a SD of NNC0662-0419 subcutaneously. |
| NNC0662-0419 (Dose 3) | EXPERIMENTAL | Participants will receive a SD of NNC0662-0419 subcutaneously. |
| Part A: Single ascending dose (SAD) | EXPERIMENTAL | Participants will receive a single dose of any of the five different dose levels of NNC0662-0419 or matching placebo in a sequential manner with the dose increasing between cohorts. |
| Part B: Multiple ascending dose (MAD) | EXPERIMENTAL | Participants will receive NNC0662-0419 once-weekly for 4 weeks at any of the four different dose levels or matching placebo in a sequential manner with the dose increasing between cohorts. |
| Name | Type | Description |
|---|---|---|
| NNC0662-0419 | DRUG | NNC0662-0419 will be administered subcutaneously. |
| Semaglutide | DRUG | Semaglutide will be administered subcutaneously. |
| NNC0662-0419 Placebo | DRUG | Placebo matched to NNC0662-0419 will be administered subcutaneously. |
| Semaglutide placebo | DRUG | Placebo matched to semaglutide will be administered subcutaneously. |
| Placebo | DRUG | Placebo will be administered subcutaneously. |
| Oral contraceptive | DRUG | An oral contraceptive Altavera \[levonorgestrel (LN) 0.15 milligram (mg) and ethinyl estradiol (EE) 0.03 mg\] will be administered orally. |
| Acetaminophen | DRUG | A single dose of acetaminophen will be administered orally. |
| Placebo (NNC0662-0419) | OTHER | Participants will receive placebo matched to NNC0662-0419 s.c. once weekly. |
Inclusion Criteria: * Male or female (sex assigned at birth, inclusive of all gender identities). * Age 18 years or above at the time of signing the informed consent. * Body mass index (BMI) greater than or equal to (≥) 30.0 kilogram per square meter (kg/m\^2) at screening. * Participant must have ...
NNC0662-0419 is an investigational small molecule being developed for type 2 diabetes, obesity, and overweight. It is being studied in clinical trials to evaluate its effects on blood sugar lowering in people with type 2 diabetes and on weight management in people living with overweight or obesity.
NNC0662-0419 is a small molecule being developed by Novo Nordisk for metabolic conditions. Its specific molecular target has not been disclosed in available clinical trial information. The drug is being studied for its effects on blood sugar and body weight in people with type 2 diabetes, overweight, and obesity.
NNC0662-0419 is being developed by Novo Nordisk A/S, a pharmaceutical company listed on the stock exchange under the ticker symbol NVO. Novo Nordisk is conducting clinical trials to evaluate the drug's safety and efficacy in metabolic conditions.
NNC0662-0419 is currently in Phase 2 clinical development. It is an investigational drug, meaning it is not approved by regulatory authorities and is still being studied in clinical trials. The drug has completed a Phase 1 first-in-human study and is now being evaluated in Phase 2 trials.
NNC0662-0419 has four clinical trials listed. NCT06737536 is a completed Phase 1 study in overweight or obesity. NCT07184632 is an active Phase 2 study in overweight or obesity. NCT07415954 is a recruiting Phase 2 study in type 2 diabetes. NCT07639021 is a recruiting Phase 2 study in obesity.
Yes, NNC0662-0419 is being studied for type 2 diabetes. A Phase 2 clinical trial (NCT07415954) is recruiting participants to compare how well different doses of the medicine lower blood sugar in people with type 2 diabetes. This trial is being conducted in multiple countries including the United States, Japan, and South Korea.